Goldman Sachs Takes 13% Stake in Biotech Firm Evotec
The Goldman Sachs Group, Inc. has disclosed its acquisition of voting rights in Evotec SE, a German biotech company.
The disclosure was made under Article 40 of the German Securities Trading Act (WpHG) and covers the group's holdings as of September 4, 2026.
The Goldman Sachs Group, Inc. now holds approximately 13.56% of Evotec SE's voting rights, with a total number of votes amounting to 177,909,559.